Verve Therapeutics (VERV) Price & Analysis

Compare

745 Followers

VERV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.86 - $11.41

Previous CloseN/A

Volume257.30K

Average Volume (3M)6.97M

Market Cap

$992.16M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta2.84

Next Earnings

Aug 07, 2025

EPS Estimate

-0.66

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding89,143,000

10 Day Avg. Volume5,716,259

30 Day Avg. Volume6,971,857

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$14.36

Price Target Upside29.02% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

AcquisitionThe definitive agreement by LLY to acquire VERV for up to $1.3 billion reflects a strong collaboration and partnership between the two companies.

Gene Editing ValidationThe acquisition of Verve Therapeutics by LLY provides significant validation of the company's gene editing capabilities.

Market PotentialThe lead indication for VERVE-102, familial hypercholesterolemia (FH), has a high prevalence, creating a large potential market.

Bears Say

Potential RisksThe main risk is a safety surprise that derails the Ph2/delays Ph3.

Stock DowngradeVERV has been downgraded to Market Perform from Outperform due to the acquisition agreement by LLY.

Uncertainty In MilestonesIt's unclear whether VERV's previously guided milestones for the second half of 2025 will occur before the deal closure.

Verve Therapeutics News

Eli Lilly completes acquisition of Verve Therapeutics

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is...

9d ago

LLY

VERV

Eli Lilly and Verve Therapeutics announce expiration of Verve tender offer

Eli Lilly (LLY) and Verve Therapeutics (VERV) announced that the tender offer to purchase all of the issued...

10d ago

LLY

VERV

Verve Therapeutics put volume heavy and directionally bearish

Bearish flow noted in Verve Therapeutics (VERV) with 4,217 puts trading, or 1.1x expected. Most active are Nov-25...

24d ago

VERV

JonesResearch lists factors for Prime Medicine continued share rally

JonesResearch says Prime Medicine (PRME) continues to rally following the management change on May 19, rallying $160% since...

27d ago

PRME

VERV

Verve Therapeutics Announces Merger and Nasdaq Delisting

Verve Therapeutics ( ($VERV) ) just unveiled an update. Verve Therapeutics has announced significant changes in its corporate...

9d ago

VERV

Verve Therapeutics Announces Retention Bonus Program for Executives

Verve Therapeutics ( ($VERV) ) has shared an announcement. Verve Therapeutics announced the establishment of a retention bonus...

19d ago

VERV

Hold Rating Issued for Verve Therapeutics Amid Eli Lilly Acquisition and Uncertain Milestones

BMO Capital analyst Kostas Biliouris downgraded the rating on Verve Therapeutics (VERV – Research Report) to a Hold...

1M ago

VERV

Verve Therapeutics downgraded to Market Perform from Outperform at BMO Capital

BMO Capital downgraded Verve Therapeutics (VERV) to Market Perform from Outperform with a $13.50 price target. Verve was...

1M ago

LLY

VERV

Crispr posts strong CTX310 data, says Chardan

Crispr Therapeutics (CRSP) reported encouraging updated Phase I data for its in vivo liver editing candidate CTX310, showing...

1M ago

LLY

CRSP

Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition

Doctors and scientists see gene editing as a new frontier. ...

2M ago

LLY

VERV

SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

ADI

Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential

Verve Therapeutics (VERV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

2M ago

VERV

Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Verve Therapeutics (VERV) to Neutral from Buy with a price target of $13.50, down from...

2M ago

VERV

Verve Therapeutics downgraded to Hold from Buy at Jefferies

Jefferies downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $11, down from $28,...

2M ago

LLY

VERV

VERV FAQ

What was Verve Therapeutics, Inc.’s price range in the past 12 months?

Verve Therapeutics, Inc. lowest stock price was $2.86 and its highest was $11.40 in the past 12 months.

What is Verve Therapeutics, Inc.’s market cap?

Verve Therapeutics, Inc.’s market cap is $992.16M.

When is Verve Therapeutics, Inc.’s upcoming earnings report date?

Verve Therapeutics, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 4 days.

How were Verve Therapeutics, Inc.’s earnings last quarter?

Verve Therapeutics, Inc. released its earnings results on May 14, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.644 by $0.294.

Is Verve Therapeutics, Inc. overvalued?

According to Wall Street analysts Verve Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Verve Therapeutics, Inc. pay dividends?

Verve Therapeutics, Inc. does not currently pay dividends.

What is Verve Therapeutics, Inc.’s EPS estimate?

Verve Therapeutics, Inc.’s EPS estimate is -0.66.

How many shares outstanding does Verve Therapeutics, Inc. have?

Verve Therapeutics, Inc. has 89,143,000 shares outstanding.

What happened to Verve Therapeutics, Inc.’s price movement after its last earnings report?

Verve Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.644. Following the earnings report the stock price went up 3.606%.

Which hedge fund is a major shareholder of Verve Therapeutics, Inc.?

Currently, no hedge funds are holding shares in VERV

Verve Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-34.26%

Trailing 12-Months

Asset Growth

-16.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Verve Therapeutics, Inc.

Verve Therapeutics (VERV) is a biotechnology company focused on developing transformative genetic medicines for cardiovascular disease. The company leverages cutting-edge gene editing technologies to create single-course gene-editing medicines that have the potential to permanently reduce the risk of coronary artery disease. Verve's innovative approach aims to address the underlying genetic causes of cardiovascular disease, which is one of the leading causes of mortality worldwide.

Verve Therapeutics (VERV) Earnings & Revenues

VERV Earnings Data >

VERV Stock 12 Month Forecast

Average Price Target

$14.36

▲(29.02%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","14":"$14","25":"$25","8.5":"$8.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8.5,14,19.5,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.28,12.258461538461537,13.236923076923077,14.215384615384615,15.193846153846152,16.17230769230769,17.150769230769228,18.12923076923077,19.107692307692307,20.086153846153845,21.064615384615387,22.043076923076924,23.021538461538462,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.28,11.516923076923076,11.753846153846153,11.99076923076923,12.227692307692307,12.464615384615383,12.701538461538462,12.938461538461539,13.175384615384615,13.412307692307692,13.649230769230769,13.886153846153846,14.123076923076923,{"y":14.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.28,11.258461538461537,11.236923076923077,11.215384615384615,11.193846153846154,11.172307692307692,11.15076923076923,11.12923076923077,11.107692307692307,11.086153846153845,11.064615384615385,11.043076923076923,11.021538461538462,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.21,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.79,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >